Juan I. Moliva
A5070140298- SARS-CoV-2 and COVID-19 Research
- Tuberculosis Research and Epidemiology
- SARS-CoV-2 detection and testing
- Animal Virus Infections Studies
- COVID-19 Clinical Research Studies
- Immunotherapy and Immune Responses
- Pneumonia and Respiratory Infections
- Mycobacterium research and diagnosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Viral gastroenteritis research and epidemiology
- Immune cells in cancer
- Viral Infections and Outbreaks Research
- Neonatal Respiratory Health Research
- Immune Cell Function and Interaction
- Immune responses and vaccinations
- Viral Infections and Vectors
- Hepatitis B Virus Studies
- Monoclonal and Polyclonal Antibodies Research
- Biochemical and Structural Characterization
- Inhalation and Respiratory Drug Delivery
- Herpesvirus Infections and Treatments
- Immunodeficiency and Autoimmune Disorders
- Phagocytosis and Immune Regulation
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Poxvirus research and outbreaks
National Institute of Allergy and Infectious Diseases
2020-2024
National Institutes of Health
2020-2024
Texas Biomedical Research Institute
2019-2024
Boston University
2023-2024
The Ohio State University
2014-2019
The Ohio State University Wexner Medical Center
2019
Biomedical Research Institute
2019
Ohio University
2016-2017
Interface (United States)
2014
Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important evaluate nonhuman primates. Nonhuman primates received 10 or 100 μg mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein SARS-CoV-2, no vaccine. Antibody T-cell responses were assessed before upper- lower-airway challenge with SARS-CoV-2. Active genomes...
The recent emergence of B.1.1.529, the Omicron variant
ABSTRACT Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative infection of a global pandemic that has led to more than 2 million deaths worldwide. The Moderna mRNA-1273 vaccine demonstrated ~94% efficacy in Phase 3 study and been approved under Emergency Use Authorization. emergence SARS-CoV-2 variants with mutations spike protein, most recently circulating isolates from United Kingdom (B.1.1.7) Republic South Africa (B.1.351), lower neutralization convalescent serum...
Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. Here, nonhuman primates (NHPs) received either no or doses ranging from 0.3 to 100 μg the mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. vaccination elicited circulating and mucosal antibody responses in a dose-dependent manner. Viral replication was significantly reduced bronchoalveolar lavages nasal swabs after SARS-CoV-2 challenge vaccinated animals most strongly...
Mpox virus (MPXV) caused a global outbreak in 2022. Although smallpox vaccines were rapidly deployed to curb spread and disease among those at highest risk, breakthrough was noted after complete immunization. Given the threat of additional zoonotic events virus's evolving ability drive human-to-human transmission, there is an urgent need for MPXV-specific vaccine that confers protection against MPXV strains related orthopoxviruses. Here, we demonstrate mRNA-lipid nanoparticle encoding set...
Abstract Antigens displayed on self-assembling nanoparticles can stimulate strong immune responses and have been playing an increasingly prominent role in structure-based vaccines. However, the development of such immunogens is often complicated by inefficiencies their production. To alleviate this issue, we developed a plug-and-play platform using spontaneous isopeptide-bond formation SpyTag:SpyCatcher system to display trimeric antigens nanoparticles, including 60-subunit Aquifex aeolicus...
A look at variant-specific boosters The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants concern (VOCs) has raised the question whether current COVID-19 vaccines protect against VOCs and if a variant specific vaccine may be needed. Of currently identified VOCs, Delta is believed to most transmissible, whereas Beta appears resistant. Corbett et al . looked effect boosting using either original WA-1 strain or variant–specific booster. Around 6 months after...
Abstract Despite the development and deployment of antibody vaccine countermeasures, rapidly-spreading SARS-CoV-2 variants with mutations at key antigenic sites in spike protein jeopardize their efficacy. The recent emergence B.1.1.529, Omicron variant1,2, which has more than 30 protein, raised concerns for escape from protection by vaccines therapeutic antibodies. A test potential countermeasures against B.1.1.529 is activity pre-clinical rodent models respiratory tract disease. Here, using...
Summary SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to antibody neutralization following immunization with ancestral spike-matched vaccines. It unclear whether boosting Omicron-specific vaccines would enhance immunity protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 4 were boosted week 41 or mRNA-Omicron. Neutralizing titers against D614G 4760 270 reciprocal ID 50 6 (peak) (pre-boost), respectively, 320 110 for Omicron. Two after boost,...
As we age, there is an increased risk for the development of tuberculosis (TB) caused by Mycobacterium (Mtb) infection. Few studies consider that age-associated changes in alveolar lining fluid (ALF) may increase susceptibility altering soluble mediators innate immunity. We assessed impact adult or elderly human ALF during Mtb infection vitro and vivo. identified amplification pro-oxidative proinflammatory pathways decreased binding capability surfactant-associated surfactant protein A...
Abstract Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. The nonhuman primate (NHP) model SARS-CoV-2 infection replicates key features human and may to define immune following vaccination. Here, NHP received either no or doses ranging from 0.3 – 100 μg mRNA-1273, a mRNA encoding the prefusion-stabilized spike (S-2P) protein encapsulated in lipid nanoparticle. mRNA-1273 vaccination elicited robust circulating mucosal antibody responses dose-dependent...
Knowledge about the impact of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elderly on mRNA vaccination response is needed to appropriately address demand for additional vaccinations in this vulnerable population. Here, we show that octogenarians, a high-risk population, mount sustained SARS-CoV-2 spike-specific immunoglobulin G (IgG) antibody 15 months following infection. This boosts levels 35-fold upon receiving single dose BNT162b2 vaccine after recovery...
The Ebola virus causes hemorrhagic fever in humans and poses a significant threat to global public health. Although two viral vector vaccines have been approved prevent disease, they are distributed the limited ring vaccination setting only indicated for prevention of infection from orthoebolavirus zairense (EBOV)—one three species that caused previous outbreaks. glycoprotein GP mediates serves as primary target neutralizing antibodies. Here, we describe universal vaccine approach using...
The elderly population is more susceptible to pulmonary infections, including tuberculosis. In this article, we characterize the impact of aging on phenotype mouse alveolar macrophages (AMs) and their response Mycobacterium Uninfected AMs were isolated from bronchoalveolar lavage young (3 mo) old (18 C57BL/6 mice. mice expressed higher mRNA levels CCL2, IFN-β, IL-10, IL-12p40, TNF-α, MIF than mice, contained IL-1β, in lining fluid. We identified two distinct AM subpopulations, a major CD11c+...
We have shown that human alveolar lining fluid (ALF) contains homeostatic hydrolases capable of altering the Mycobacterium tuberculosis cell wall and subsequently its interaction with macrophages. Neutrophils are also an integral part host immune response to M. infection. Here we show lung mucosa influences neutrophils, enhancing intracellular killing ALF-exposed up-regulating expression tumor necrosis factor interleukin 8. In contrast, does not induce neutrophil apoptosis or necrosis,...
Mycobacterium tuberculosis (M.tb), the causative agent of (TB), is leading killer due to an infectious organism. bovis bacillus Calmette-Guérin (BCG) only vaccine approved against TB, however, its efficacy pulmonary TB poor. While BCG currently inoculated intradermally, natural route M.tb infection through lung. Excessive lung pathology caused by inoculation has prevented use this immunization route. Here, we show that selective chemical treatment with petroleum ether removes inflammatory...